The pharmaceutical industry is accelerating towards "intelligent manufacturing", and pharmaceutical machinery companies are also taking active actions in this field

【Pharmaceutical Network Market Analysis】New technologies such as the Internet of Everything, big data, and artificial intelligence are currently being used in the manufacturing industry, which has brought new changes
to many industries.
Among them, the pharmaceutical industry is undoubtedly one of
the most affected areas.
It is reported that at present, many pharmaceutical companies have begun to use digitalization, artificial intelligence, etc.
, to accelerate the transformation and upgrading
from "manufacturing" to "intelligent manufacturing".
It is worth noting that at the same time, companies that are spending heavily on smart engineering are becoming more and more numerous
.
The pharmaceutical industry is accelerating from "manufacturing" to "intelligent manufacturing"! For example, in September, the Hopfei County Branch of Lunan Pharmaceutical Group officially put into operation the production line of oral liquid strips of traditional Chinese medicine, which can process 25,000 tons of traditional Chinese medicinal materials annually and produce 3 billion bags
of oral liquid per year.
It is reported that this fully digital production line integrates the informationization, integration and network data system of the pretreatment of Chinese herbal medicines, with more than 8,000 control points and a self-control and commissioning rate of 95%, realizing the 'precise and intelligent manufacturing'
of the pretreatment process of traditional Chinese medicine production.
Qilu Pharmaceutical is also accelerating the construction of a high-end intelligent processing and manufacturing center project
this year.
It is understood that the project is expected to have a total investment of nearly 700 million yuan, and after completion, it is expected to become a highly automated and intelligent pharmaceutical production line in China, helping pharmaceutical companies achieve stable production and overproduction, and improve production efficiency
.
In addition to the use of digital technology and intelligent platforms in production, since 2022, a number of domestic and foreign pharmaceutical companies have announced that they will cooperate with technology companies and artificial intelligence platforms to accelerate their entry into the field of AI drug research and development
.
On October 18, GSK announced an expanded three-year collaboration agreement with U.
S.
precision medicine company Tempus, which will have access to Tempus' artificial intelligence platform, including data
that identifies patients and their situations 。 On July 23, Yunnan Baiyao and Huawei Technologies Co.
, Ltd.
signed the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D" in Fuzhou City, Fujian Province, to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development.
.
.
On the whole, "intelligent manufacturing" has become a popular investment track for enterprises in the pharmaceutical and medical industry, and a large number of pharmaceuticals are trying to make more beneficial attempts
in reducing costs, shortening research and development cycles, reducing risks, and ensuring production safety by investing in artificial intelligence companies and cooperating with artificial intelligence companies.
However, in the context of pharmaceutical companies accelerating from "manufacturing" to "intelligent manufacturing", the industry also proposed that intelligent upgrading is not as simple as adopting new technologies from parts and fragments, or installing several intelligent equipment.

It is understood that in fact, as a pharmaceutical equipment industry closely related to the development of the pharmaceutical industry, at the moment when pharmaceutical companies vigorously promote the intelligence of high-end drug production, they have already begun to actively deploy in intelligent manufacturing, and accelerate the transformation
from "manufacturing" to "intelligent manufacturing".
For example, Canaan Technology has invested a total of 1 billion yuan to build an intelligent medical equipment manufacturing project
.
It is reported that the project aims at the core areas of the health industry such as granulation line equipment and solid preparation equipment, and can achieve an annual output of 4,000 sets of high-end pharmaceutical equipment after being put into operation, and the output value of the enterprise will be increased by 5 times
.
On August 15, the precision medical equipment intelligent manufacturing base project invested and operated by Chutian Changxing Precision Manufacturing (Changsha) Co.
, Ltd.
, a holding subsidiary of Chutian Technology, has also officially signed a contract to settle in Ningxiang Economic and Technological Development Zone, which will be built in phases, focusing on the layout and development of precision transmission parts products and industrial robots
.
Conclusion In general, pharmaceutical equipment companies are taking active actions in "intelligent manufacturing", and the industry believes that this will also play a key role
in the intelligent upgrading of the pharmaceutical industry.
In the future, with the continuous development of intelligent technology, pharmaceutical equipment will continue to help pharmaceutical companies liberate their workforce, and will also promote the production of the pharmaceutical industry to be more energy-efficient, efficient and safe.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.